⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8228083 | 1.00 | — | — | |
| SCHEMBL4694174 | 1.00 | — | — | |
| SCHEMBL9127797 | 1.00 | — | — | |
| SCHEMBL353876 | 1.00 | — | — | |
| SCHEMBL932838 | 1.00 | — | — | |
| SCHEMBL24611418 | 1.00 | — | — | |
| SCHEMBL8742318 | 1.00 | — | — | |
| SCHEMBL8241314 | 1.00 | — | — | |
| SCHEMBL13361567 | 1.00 | — | — | |
| SCHEMBL2218234 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391675-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20220089572-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. | 2022-03-24 | — | — | US | disclosed |
| EP-2480247-B1 | NOVEL NPR-B AGONISTS | SHIRE ORPHAN THERAPIES GMBH (DE) | 2020-02-12 | — | — | EP | disclosed |
| EP-3555096-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | Janssen Pharmaceutica NV (BE) | 2019-10-23 | — | — | EP | disclosed |
| US-10196423-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| US-10196423-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
| US-20180334477-A1 | NPR-B Agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-22 | — | — | US | disclosed |
| WO-2018112382-A1 | IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-21 | — | — | WO | disclosed |
| US-9982016-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-9982016-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2018-05-29 | — | — | US | disclosed |
| US-20110077381-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077381-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077381-A1 | NOVEL NPR-B AGONISTS | ALCON RESEARCH, LTD. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| US-20080175914-A1 | Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED | 2008-07-24 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-20040132755-A1 | Isoxazoles and uses thereof | VERTEX PHARMACEUTICALS INCOCRPORATED | 2004-07-08 | — | — | US | disclosed |
| US-6355631-B1 | TREATMENT OF PSYCHOSIS AND SCHIZOPHRENIA | AVENTIS PHARMA S.A. (FR) | 2002-03-12 | — | — | US | disclosed |